Navigation Links
Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Date:1/4/2008

- Studies to investigate safety and efficacy in treatment of multi-drug

resistant infections -

NEW HAVEN, Conn., Jan. 4 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a biopharmaceutical company focused on the development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the enrolment of the first patients in two separate Phase 2 clinical trials. The studies will evaluate the safety and efficacy of RX-1741 in the treatment of Community-Acquired Pneumonia (CAP), and separately in the outpatient treatment of Uncomplicated Skin and Skin Structure Infections (uSSSI). RX-1741 is the Company's first antibiotic program developed using its proprietary technology platform.

RX-1741 is an oxazolidinone antibiotic that exhibits activity against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive organisms, and has demonstrated both greater spectrum and potency of activity than the currently marketed product of the same class, Zyvox(R) (linezolid). Discovered using proprietary knowledge of the three dimensional structure of a key area of the ribosome, the 50S subunit, Rib-X believes that RX-1741 will demonstrate a high level of effectiveness against resistant microbes.

"These two studies represent important milestones for Rib-X," said Dr. Susan Froshauer, President and CEO of Rib-X Pharmaceuticals. "RX-1741 is the first of many compounds that Rib-X intends to design and develop in response to the alarming growth of drug resistant microbial pathogens found both in the hospital and in the community. This MRSA-active agent will satisfy a critical need for physicians and their patients because current treatment options are very limited, particularly for orally active agents," said Dr. Froshauer.

CAP Study Design

The CAP study is a Phase 2, multicenter, randomized, double-blind study designed to evaluate the safety and efficacy
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
2. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
3. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
4. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
5. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
8. Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
9. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 In response to recent ... and The US Postal Service to no longer ... ,select agents, by the CDC, Marken reaffirmed today ... sensitive shipments. Marken uses its flexible ... and certified personnel to ensure the safe and ...
(Date:8/26/2015)... Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens, ... at the Sidoti & Company Emerging Growth Conference on ... held at the New York Marriott Marquis. ... available through the investor relations section of Roka Bioscience,s ...
(Date:8/26/2015)... Aug. 26, 2015 Intrexon Corporation (NYSE: ... the closing of its previously announced public offering of ... underwriters of their option to purchase an additional 731,707 ... of $41.00 per share.  The exercise of the underwriters, ... stock sold by Intrexon to 5,609,756 shares and increased ...
(Date:8/26/2015)... , August 26, 2015 ... biggest factors fueling the optimism in biotech,s forecast ... collaborations and life sciences advancements.  Active biotechnology & ... Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: ... SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: RPTP ...
Breaking Biology Technology:Marken Ensures Safe Transportation Of Select Agents And Toxins 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... Thermo Fisher,Scientific Inc. (NYSE: TMO ), the world ... the 2008 Merrill Lynch Global Pharmaceutical,Biotechnology & Medical Device ... York City. The company will present on Thursday, February ... president and chief executive officer of Thermo,Fisher Scientific, will ...
... BD (Becton,Dickinson and Company) (NYSE: BDX ) announced ... today, elected Basil L. Anderson,Marshall O. Larsen, Gary A. ... of Directors. The BD Board currently consists of 13 ... Edward J. Ludwig,Chairman, President and Chief Executive Officer., ...
... SANTA CRUZ, Calif., Jan. 29 Expanding ... career resources to post-graduate and,alumni candidates, Bio Career ... joined forces., On Jan. 28, Emory University, ... Bio Career Center family, rounding out an,already elite ...
Cached Biology Technology:Thermo Fisher Scientific to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2BD Announces Results of Shareholder Votes at Annual Meeting 2Online Career Site for Life Science Professionals Continues Growth 2
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... it survives on a diet of roundworm. But ... associate professor of biomedical engineering at the University of Tennessee, ... fighter. Zhang and his team have discovered that ... stimulating the immune system and killing tumors. The findings are ...
... NEW YORK, Dec. 4, 2012 A recent ABC News ... systems—to help ensure greater security in large childcare facilities. While ... stave off unwanted visitors and protect children from exiting the ... those who come in and out of the building. Slava ...
... of Seville (Spain) have developed a technique for estimating grape ... forward an index for identifying the ripeness of seeds without ... to decide the best moment for picking. The normal ... analysis. But this is a long and tedious task that ...
Cached Biology News:University of Tennessee researchers find fungus has cancer-fighting power 2Slava Volman Responds to Use of Biometrics for Security in Childcare Facilities 2A digital portrait for grapes indicates their ripeness 2
... (RNA polymers) are prepared ... of the enzyme, polynucleotide ... and the appropriate, ribonucleoside ... the exception of catalog ...
... Heavy duty stainless-steel shaker flask clips, ... high speeds. All clips are equipped ... (over 1L.) also include a bottom retainer ... prevent scratching of expensive glassware. Clips ...
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
... Bullseye Red Taq DNA Polymerase ... exhibits very high activity in primer extension ... contains a red dye which provides easy ... enzyme was added and allows confirmation of ...
Biology Products: